A series of preclinical studies show that a new compound, SHP1705, targets circadian clock proteins hijacked by glioblastoma stem cells, impairing the cancer cells' ability to survive and grow.

A chemical cage suppresses the activity of a biological clock regulator in the dark and releases it with light, showing potential for future treatments of circadian-clock-related diseases. Researchers ...

A series of preclinical studies show that a new compound, SHP1705, targets circadian clock proteins hijacked by glioblastoma stem cells, impairing the cancer cells’ ability to survive and grow.